Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)
Close on Nov 17, 2026Market cap $37.94MP/E –Yield –
Yarrow Bioscience operating margin
Operating margin is operating income as a percentage of revenue.
Yarrow Bioscience's operating margin for the twelve months ending Jun 30, 2025 was -8949.6%. For fiscal 2025 it was -5219.1%, against -8710.0% the year before. The highest annual figure on record is -645.9% in fiscal 2017.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -5219.1% | +3490.9 |
| FY2024 | Dec 31, 2024 | -8710.0% | −1809.5 |
| FY2023 | Dec 31, 2023 | -6900.5% | +289.3 |
| FY2022 | Dec 31, 2022 | -7189.7% | −3010.2 |
| FY2021 | Dec 31, 2021 | -4179.5% | −2976.5 |
| FY2020 | Dec 31, 2020 | -1203.0% | +20438.8 |
| FY2019 | Dec 31, 2019 | -21641.8% | −19558.5 |
| FY2018 | Dec 31, 2018 | -2083.2% | −1437.4 |
| FY2017 | Dec 31, 2017 | -645.9% | +1480.6 |
| FY2016 | Dec 31, 2016 | -2126.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -3197.9% | +12004.4 |
| Q1 FY2026 | Mar 31, 2026 | -4437.2% | +6381.8 |
| Q2 FY2025 | Jun 30, 2025 | -10930.4% | −5679.9 |
| Q1 FY2025 | Mar 31, 2025 | -4553.0% | +2977.6 |
| Q4 FY2024 | Dec 31, 2024 | -15202.4% | −6212.9 |
| Q3 FY2024 | Sep 30, 2024 | -10819.0% | −5350.6 |
| Q2 FY2024 | Jun 30, 2024 | -5250.5% | +2392.5 |
| Q1 FY2024 | Mar 31, 2024 | -7530.6% | −1596.3 |
| Q4 FY2023 | Dec 31, 2023 | -8989.5% | +124077.2 |
| Q3 FY2023 | Sep 30, 2023 | -5468.4% | +120.2 |
| Q2 FY2023 | Jun 30, 2023 | -7643.0% | −1066.0 |
| Q1 FY2023 | Mar 31, 2023 | -5934.3% | −1051.8 |
| Q4 FY2022 | Dec 31, 2022 | -133066.7% | −129826.4 |
| Q3 FY2022 | Sep 30, 2022 | -5588.6% | +2506.9 |
| Q2 FY2022 | Jun 30, 2022 | -6577.0% | −3342.4 |
| Q1 FY2022 | Mar 31, 2022 | -4882.6% | −640.4 |
| Q4 FY2021 | Dec 31, 2021 | -3240.3% | −2727.3 |
| Q3 FY2021 | Sep 30, 2021 | -8095.5% | −7376.9 |
| Q2 FY2021 | Jun 30, 2021 | -3234.6% | −1804.2 |
| Q1 FY2021 | Mar 31, 2021 | -4242.2% | −1962.8 |
| Q4 FY2020 | Dec 31, 2020 | -513.0% | +27213.6 |
| Q3 FY2020 | Sep 30, 2020 | -718.6% | +4438.5 |
| Q2 FY2020 | Jun 30, 2020 | -1430.3% | −1339.9 |
| Q1 FY2020 | Mar 31, 2020 | -2279.4% | +380.6 |
| Q4 FY2019 | Dec 31, 2019 | -27726.7% | −27385.2 |
| Q1 FY2019 | Mar 31, 2019 | -5157.1% | −4240.2 |
| Q2 FY2018 | Jun 30, 2018 | -90.4% | +1296.0 |
| Q1 FY2018 | Mar 31, 2018 | -2660.0% | −1422.8 |
| Q4 FY2017 | Dec 31, 2017 | -341.5% | – |
| Q3 FY2017 | Sep 30, 2017 | -916.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -1386.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -1237.2% | – |
See a number that looks wrong?